Literature DB >> 35202484

PharmVar GeneFocus: CYP3A5.

Cristina Rodriguez-Antona1,2, Jessica L Savieo3, Volker M Lauschke4,5,6, Katrin Sangkuhl7, Britt I Drögemöller8,9,10, Danxin Wang11, Ron H N van Schaik12, Andrei A Gilep13,14, Arul P Peter15, Erin C Boone16, Bronwyn E Ramey17, Teri E Klein7, Michelle Whirl-Carrillo7, Victoria M Pratt18, Andrea Gaedigk16,19.   

Abstract

The Pharmacogene Variation Consortium (PharmVar) catalogs star (*) allele nomenclature for the polymorphic human CYP3A5 gene. Genetic variation within the CYP3A5 gene locus impacts the metabolism of several clinically important drugs, including the immunosuppressants tacrolimus, sirolimus, cyclosporine, and the benzodiazepine midazolam. Variable CYP3A5 activity is of clinical importance regarding tacrolimus metabolism. This GeneFocus provides a CYP3A5 gene summary with a focus on aspects regarding standardized nomenclature. In addition, this review also summarizes recent changes and updates, including the retirement of several allelic variants and provides an overview of how PharmVar CYP3A5 star allele nomenclature is utilized by the Pharmacogenomics Knowledgebase (PharmGKB) and the Clinical Pharmacogenetics Implementation Consortium (CPIC).
© 2022 The Authors. Clinical Pharmacology & Therapeutics © 2022 American Society for Clinical Pharmacology and Therapeutics.

Entities:  

Year:  2022        PMID： 35202484      PMCID： PMC9399309          DOI： 10.1002/cpt.2563

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN： 0009-9236            Impact factor:   6.903


  76 in total

1.  A prospective, randomized trial of tacrolimus/prednisone versus tacrolimus/prednisone/mycophenolate mofetil in renal transplant recipients.

Authors:  R Shapiro; M L Jordan; V P Scantlebury; C Vivas; J W Marsh; J McCauley; J Johnston; P Randhawa; W Irish; H A Gritsch; R Naraghi; T R Hakala; J J Fung; T E Starzl
Journal:  Transplantation       Date:  1999-02-15       Impact factor: 4.939

2.  CYP3A5 genotype has an impact on the metabolism of the HIV protease inhibitor saquinavir.

Authors:  F Josephson; A Allqvist; M Janabi; J Sayi; E Aklillu; M Jande; M Mahindi; J Burhenne; Y Bottiger; L L Gustafsson; W E Haefeli; L Bertilsson
Journal:  Clin Pharmacol Ther       Date:  2007-02-28       Impact factor: 6.875

3.  A Naturally Occurring Isoform-Specific Probe for Highly Selective and Sensitive Detection of Human Cytochrome P450 3A5.

Authors:  Jing-Jing Wu; Yun-Feng Cao; Liang Feng; Yu-Qi He; James Y Hong; Tong-Yi Dou; Ping Wang; Da-Cheng Hao; Guang-Bo Ge; Ling Yang
Journal:  J Med Chem       Date:  2017-05-01       Impact factor: 7.446

Review 4.  Recommendations for Clinical CYP2C19 Genotyping Allele Selection: A Report of the Association for Molecular Pathology.

Authors:  Victoria M Pratt; Andria L Del Tredici; Houda Hachad; Yuan Ji; Lisa V Kalman; Stuart A Scott; Karen E Weck
Journal:  J Mol Diagn       Date:  2018-02-21       Impact factor: 5.568

5.  Characterization of a cDNA encoding a new member of the glucocorticoid-responsive cytochromes P450 in human liver.

Authors:  J D Schuetz; D T Molowa; P S Guzelian
Journal:  Arch Biochem Biophys       Date:  1989-11-01       Impact factor: 4.013

6.  CYP2C8, CYP2C9, and CYP2C19 Characterization Using Next-Generation Sequencing and Haplotype Analysis: A GeT-RM Collaborative Project.

Authors:  Andrea Gaedigk; Erin C Boone; Steven E Scherer; Seung-Been Lee; Ibrahim Numanagić; Cenk Sahinalp; Joshua D Smith; Sean McGee; Aparna Radhakrishnan; Xiang Qin; Wendy Y Wang; Emily G Farrow; Nina Gonzaludo; Aaron L Halpern; Deborah A Nickerson; Neil A Miller; Victoria M Pratt; Lisa V Kalman
Journal:  J Mol Diagn       Date:  2022-02-05       Impact factor: 5.341

7.  Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus.

Authors:  Dennis A Hesselink; Ron H N van Schaik; Ilse P van der Heiden; Marloes van der Werf; Peter J H Smak Gregoor; Jan Lindemans; Willem Weimar; Teun van Gelder
Journal:  Clin Pharmacol Ther       Date:  2003-09       Impact factor: 6.875

8.  CYP3A5 genotype is not associated with a higher risk of acute rejection in tacrolimus-treated renal transplant recipients.

Authors:  Dennis A Hesselink; Ron H N van Schaik; Madelon van Agteren; Johannes W de Fijter; Anders Hartmann; Martin Zeier; Klemens Budde; Dirk R J Kuypers; Przemyslav Pisarski; Yann Le Meur; Richard D Mamelok; Teun van Gelder
Journal:  Pharmacogenet Genomics       Date:  2008-04       Impact factor: 2.089

9.  CYP3A5 mediates basal and acquired therapy resistance in different subtypes of pancreatic ductal adenocarcinoma.

Authors:  Elisa M Noll; Christian Eisen; Albrecht Stenzinger; Elisa Espinet; Alexander Muckenhuber; Corinna Klein; Vanessa Vogel; Bernd Klaus; Wiebke Nadler; Christoph Rösli; Christian Lutz; Michael Kulke; Jan Engelhardt; Franziska M Zickgraf; Octavio Espinosa; Matthias Schlesner; Xiaoqi Jiang; Annette Kopp-Schneider; Peter Neuhaus; Marcus Bahra; Bruno V Sinn; Roland Eils; Nathalia A Giese; Thilo Hackert; Oliver Strobel; Jens Werner; Markus W Büchler; Wilko Weichert; Andreas Trumpp; Martin R Sprick
Journal:  Nat Med       Date:  2016-02-08       Impact factor: 53.440

10.  Sex Differences in the Blood Concentration of Tacrolimus in Systemic Lupus Erythematosus and Rheumatoid Arthritis Patients with CYP3A5*3/*3.

Authors:  Ayano Ito; Yuko Okada; Tadahiro Hashita; Tohru Aomori; Keiju Hiromura; Yoshihisa Nojima; Tomonori Nakamura; Takuya Araki; Koujirou Yamamoto
Journal:  Biochem Genet       Date:  2017-03-21       Impact factor: 1.890
View more
  1 in total

Review 1.  Why We Need to Take a Closer Look at Genetic Contributions to CYP3A Activity.

Authors:  Qinglian Zhai; Maaike van der Lee; Teun van Gelder; Jesse J Swen
Journal:  Front Pharmacol       Date:  2022-06-16       Impact factor: 5.988
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.